BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20949623)

  • 1. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
    Ault KA; Joura EA; Kjaer SK; Iversen OE; Wheeler CM; Perez G; Brown DR; Koutsky LA; Garland SM; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Majewski S; Muñoz N; Sings HL; Harkins K; Rutkowski MA; Haupt RM; Garner EI;
    Int J Cancer; 2011 Mar; 128(6):1344-53. PubMed ID: 20949623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.
    Stoler MH; Vichnin MD; Ferenczy A; Ferris DG; Perez G; Paavonen J; Joura EA; Djursing H; Sigurdsson K; Jefferson L; Alvarez F; Sings HL; Lu S; James MK; Saah A; Haupt RM;
    Int J Cancer; 2011 Mar; 128(6):1354-62. PubMed ID: 20506504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
    Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
    Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears.
    Derchain SF; Rabelo-Santos SH; Sarian LO; Zeferino LC; de Oliveira Zambeli ER; do Amaral Westin MC; de Angelo Andrade LA; Syrjänen KJ
    Gynecol Oncol; 2004 Dec; 95(3):618-23. PubMed ID: 15581973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
    Ault KA;
    Lancet; 2007 Jun; 369(9576):1861-1868. PubMed ID: 17544766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
    Joura EA; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris D; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Miller D; Monsonego J; Munoz N; Myers E; Paavonen J; Pitisuttithum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
    Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1997-2008. PubMed ID: 25274978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic Outcomes in HPV-Positive and Cervical Cytology- Negative Women - Screening Results in Northern Thailand.
    Vijakururote L; Suprasert P; Srisomboon J; Siriaunkgul S; Settakorn J; Rewsuwan S
    Asian Pac J Cancer Prev; 2015; 16(16):7271-5. PubMed ID: 26514523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology.
    Komatsu H; Oishi T; Osaku D; Sawada M; Kudoh A; Nonaka M; Chikumi J; Sato S; Harada T
    Acta Cytol; 2018; 62(5-6):405-410. PubMed ID: 29990964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
    FUTURE II Study Group
    J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
    Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
    Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
    Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
    Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.
    Hariri S; Unger ER; Schafer S; Niccolai LM; Park IU; Bloch KC; Bennett NM; Steinau M; Johnson ML; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):393-9. PubMed ID: 25416715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
    Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
    Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group
    N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.